Applying Health Plan Best Practices to Improve Outcomes in Atopic Dermatitis Across the Spectrum of Patient Types: Atopic Dermatitis Guidelines Update for Payers

Release Date: March 1, 2024
Expiration Date: August 31, 2025
Estimated Time to Complete Activity: 1.0 hour
Compatible with all modern browsers and mobile devices

Expert Faculty Presenters:


	Zelma C. Chiesa Fuxench, MD, MSCE, FAAD Assistant Professor of Dermatology Department of Dermatology University of Pennsylvania Perelman School of Medicine Click here for biography

	Gary M. Owens, MD President Gary Owens Associates, Inc. Click here for biography

	Silena NEA Ambassador

Target Audience
This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
With a rapidly evolving treatment armamentarium, payer decision makers need to be kept up to date on changing clinical guidelines. Evidenced-based guidelines are needed to aid treatment access coverage policies that will help ensure timely access to appropriate treatments within insured patient populations. This activity features multi-specialty, multi-professional expert faculty collaborating on presentations and discussion of recent insights into evolving atopic dermatitis (AD) guidelines.

Educational Objectives
After completing this activity, the participant should be better able to:

Utilize evidence-based guides for assessing disease severity and treatment selection to improve outcomes in AD management
Appraise the evidence for the association between AD and comorbid conditions

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE), the National Eczema Association (NEA), and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-24-034-H01-P
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

*Name of Faculty*	*Reported Financial Relationship*
Zelma C. Chiesa Fuxench, MD, MSCE	Consultant, advisor, or speaker for AbbVie, Beirsdorf, Incyte, National Eczema Association, Pfizer Researcher for Lilly
Gary M. Owens, MD	Consultant, advisor, or speaker for Sanofi, Regeneron Independent Contractor for Plans4Care, Baxter, ICON
Silena	Silena has no relevant financial relationships.

The PACE planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.